FINWIRES · TerminalLIVE
FINWIRES

$XNCR

3 stories mentioning XNCRUpdated just now

Every FINWIRES story that references XNCR, newest first.

Sectors

Sector Update: Healthcare Stocks Mixed Late Afternoon

Healthcare stocks were mixed late Friday afternoon, with the NYSE Healthcare Index unchanged and the State Street Health Care Select Sector SPDR ETF (XLV) decreasing 0.3%.The iShares Biotechnology ETF (IBB) was up 0.1%.In corporate news, Eli Lilly's (LLY) long-term GLP-1 franchise is unlikely to face significant pressure from generic GLP-1 drugs, as manufacturing constraints should limit generic market penetration while the company's next-generation therapies are expected to preserve its market leadership, UBS Securities said in a note. Lilly shares were up 0.7%.Intuitive Surgical (ISRG) shares fell nearly 14%. Growth in the company's da Vinci robotic surgery procedures in the US moderated due in part to changes in Affordable Care Act premium subsidies, even as it reported better-than-expected quarterly results.GSK (GSK) shares were down 2.1% after it said Friday it will discontinue development of camlipixant for refractory chronic cough after the drug produced mixed results in the phase 3 CALM-1 and CALM-2 trials.Xencor (XNCR) shares jumped about 13% after the firm said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology Congress in October.

$GSK$ISRG$LLY$XNCR
Sectors

Sector Update: Healthcare

Healthcare stocks were softer late Friday afternoon, with the NYSE Healthcare Index 0.1% lower and the State Street Health Care Select Sector SPDR ETF (XLV) down 0.3%.The iShares Biotechnology ETF (IBB) was fractionally lower.In corporate news, Xencor (XNCR) shares jumped 11% after the firm said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology Congress in October.

$XNCR
Wire

Xencor's Cancer Drug Study Selected for Oral Presentation at ESMO; Shares Rise

Xencor (XNCR) said Friday that phase 1 results for its experimental cancer therapy XmAb819 in advanced clear cell renal cell carcinoma have been selected for a proffered paper oral presentation at the European Society of Medical Oncology, or ESMO, Congress in October.The company said expansion cohorts are evaluating intravenous doses to support selection of a recommended dose for a planned phase 3 study in advanced clear cell renal cell carcinoma, which is expected to begin in 2027.Shares of Xencor were up 8.6% in Friday afternoon trading.Price: $16.24, Change: $+1.28, Percent Change: +8.56%

$XNCR

Track with the FINWIRES app suite